89bio Inc - Asset Resilience Ratio
89bio Inc (ETNB) has an Asset Resilience Ratio of 71.60% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2024)
This chart shows how 89bio Inc's Asset Resilience Ratio has changed over time. Check strategic asset allocation of 89bio Inc to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down 89bio Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ETNB market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $432.09 Million | 71.6% |
| Total Liquid Assets | $432.09 Million | 71.60% |
Asset Resilience Insights
- Very High Liquidity: 89bio Inc maintains exceptional liquid asset reserves at 71.60% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
89bio Inc Industry Peers by Asset Resilience Ratio
Compare 89bio Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
ALTEOGEN Inc
KQ:196170 |
Biotechnology | 55.57% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 34.94% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
Annual Asset Resilience Ratio for 89bio Inc (2020–2024)
The table below shows the annual Asset Resilience Ratio data for 89bio Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 65.57% | $313.89 Million | $478.69 Million | +21.52pp |
| 2023-12-31 | 44.06% | $262.71 Million | $596.27 Million | -23.47pp |
| 2022-12-31 | 67.52% | $132.91 Million | $196.82 Million | +7.01pp |
| 2021-12-31 | 60.51% | $98.29 Million | $162.42 Million | +10.08pp |
| 2020-12-31 | 50.43% | $106.45 Million | $211.07 Million | -- |
About 89bio Inc
89bio, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of metabolic dysfunction-associated steatohepatitis and hypertriglyceridemia. 89bio, Inc. was formerly kn… Read more